1. Blood Adv. 2021. Coevolving JAK2V617F+ relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case
  2. J Immunother Cancer. 2021. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
  3. Blood. 2021. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
  4. Cancer Cell. 2021. A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation
  5. Clin Cancer Res. 2021. A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
  6. Cancer Immunol Immunother. 2021. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors
  7. Clin Cancer Res. 2021. Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for recurrent glioblastoma patients
  8. J Immunother Cancer. 2020. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
  9. Int J Radiat Oncol Biol Phys. 2020. A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma
  10. STAR Protocols. 2020. High-Throughput Mass Cytometry Staining for Immunophenotyping Clinical Samples
  11. J Biol Methods. 2020. Standardized 11-color flow cytometry panel for the functional phenotyping of human T regulatory cells
  12. Cytometry A. 2019. A modified injector and sample acquisition protocol can improve data quality and reduce inter-instrument variability of the Helios Mass Cytometer
  13. 2019. Anti-PD-1 immunotherapy-Induced flare of a known underlying relapsing vasculitis mimicking recurrent cancer
  14. J Biol Methods. 2019. Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry
  15. 2019. Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features
  16. Cell Tissue Bank 2018. Separation, banking, and quality control of peripheral blood mononuclear cells from whole blood of melanoma patients
  17. Oncoimmunology. 2018. Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma
  18. J Immunother Cancer. 2018. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
  19. Cancer Immunol Res. 2017. Angiopoietin-2 as a biomarker and target for immune checkpoint therapy
  20. Cancer. 2017. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study 
  21. Cytotechnology. 2017. Development of an 8-color antibody panel for functional phenotyping of human CD8+ cytotoxic T cells from peripheral blood mononuclear cells   
  22. N Engl J Med. 2016. Ipilimumab for patients with relapse after allogeneic transplantation
  23. Br J Cancer. 2016. Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
  24. J Immunother Cancer. 2016. Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients
  25. Cancer Immunol Res. 2016. Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes